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Background: The aim of this study was to evaluate the recurrence pattern after skin-sparing mastectomy (SSM)
and immediate breast reconstruction (IBR) using transverse rectus abdominis musculocutaneous (TRAM) flap in
patients with invasive breast cancer.
Methods: From 1995 to 2010, patients with invasive breast cancer who underwent SSM followed by IBR using
TRAM flap were retrospectively reviewed. The pattern of the first recurrence event was recorded.
Results: We identified 249 consecutive patients with invasive breast cancer, two-thirds of whom (67.1%) were
diagnosed with stage II or stage III disease. During a median follow-up period of 53 months, three (1.2%) local, 13
(5.2%) regional, 34 (13.7%) distant, and five (2.0%) concurrent locoregional and distant recurrences were observed.
The median time to recurrences was 26 months (range, 2 to 70 months) for all recurrences, 23 months (range, 2 to
64 months) for locoregional recurrences, and 26 months (range, 8 to 70 months) for distant recurrences. All local
recurrent lesions were detectable by careful physical examination, and detection of local recurrence suggested the
presence of distant metastasis (60.0%). In contrast to distant metastasis, the risk of locoregional recurrence did not
increase significantly with an increase in disease stage. The 5-year overall, locoregional relapse-free, and distant
relapse-free survival rates were 89.7%, 90.8%, and 81.6%, respectively.
Conclusions: SSM followed by immediate reconstruction using TRAM flap is an oncologically safe procedure even
in patients with advanced-stage disease. Detection of local recurrence is crucial and can be aided by a thorough
physical examination.
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Skin-sparing mastectomy (SSM) followed by immediate
breast reconstruction (IBR) has become a common and
widely used procedure for patients with ductal carcinoma
in situ and early-stage breast cancer [1]. The oncological
safety and superior cosmetic outcomes of this approach
have been demonstrated in several studies [2,3]. The* Correspondence: nugaticc@gmail.com
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reproduction in any medium, provided the oruse of this approach is still debated, however, and the
implementation of SSM for advanced-stage disease has
not been thoroughly investigated [4-6].
One of the major concerns regarding SSM and IBR is
local recurrence [7,8]. Inadequate skin excision after
SSM may increase the theoretical risk of recurrence.
Another concern is that IBR may obscure a recurrent
lesion, thereby delaying its diagnosis and subsequent
management [9,10]. Furthermore, no clear consensus has
been established regarding the ideal screening tool for
reconstructed breast tissue [9]. Unsurprisingly, therefore,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SSM and IBR may result in inferior oncological outcomes,
especially in patients with more advanced disease
stages [11].
Among the various types of breast reconstruction, use
of the transverse rectus abdominis musculocutaneous
(TRAM) flap is a popular choice for either immediate
or delayed reconstruction [10]. The flap transfers suffi-
cient tissue to create a breast with excellent bulk and
simultaneously provides an abdominoplasty. Use of the
TRAM flap is thus the most common reconstruction
method applied in our institution. Most published studies
that investigated SSM and IBR enrolled patients using
some degree of selection (either early-stage patients or
advanced-stage patients were included), evaluated a small
number of cases, and employed more than one type of
reconstruction method [1,11,12]. The patients in the
present study were relatively unselected and received
only one type of reconstruction.
The aim of this study was to evaluate the incidence
and pattern of recurrence in a broad spectrum of breast
cancer patients regardless of the tumor stage after
treatment with SSM and IBR with TRAM flap.Methods
Patients
Between August 1995 and December 2010, data on all
breast cancer patients who underwent SSM and IBR
using TRAM flap at Kaohsiung Veterans General Hospital
were retrospectively reviewed. In total, 335 patients were
treated during this period. Patients with local recurrence
following previous lumpectomy or mastectomy for prophy-
laxis and those with a follow-up period < 2 years were
excluded (n = 38). Patients with purely in situ disease
were also excluded (n = 48). A total of 249 patients
with invasive breast cancer were enrolled in this study.
Diagnoses of all patients were pathologically confirmed,
and the disease was staged according to the seventh
edition of the American Joint Committee on Cancer
staging system [13]. Inform consent was obtained from
all patients before operation. This study was approved
by the institutional review board in Kaohsiung Veterans
General Hospital.Surgical treatment
SSM was defined as removal of the whole breast tissue,
the nipple–areola complex, the biopsy scar, and the skin
overlying superficial tumors. The remaining native skin
envelope and inframammary fold were preserved. Axillary
lymph node dissection was subsequently performed via
an axillary incision. All IBR procedures were performed
using a pedicled TRAM flap. Patients were all counseled
preoperatively regarding the types of mastectomy andreconstruction options. Risks and benefits of different
methods were thoroughly explained.
Neoadjuvant and adjuvant treatment
Neoadjuvant chemotherapy with an anthracycline-based
regimen was considered for patients presenting with
locally advanced disease. The number of neoadjuvant
chemotherapy cycles depended upon individual clinical
response and the surgeon’s discretion. Adjuvant chemo-
therapy was indicated for patients with positive lymph
node status. Among patients without lymph node involve-
ment, chemotherapy was considered for those with un-
favorable prognostic features such as negative estrogen
receptor status, HER-2 overexpression, high histologic
grade, presence of lymphovascular invasion, and large
tumor size. Treatment was commenced once patients
recovered from surgery. Anthracycline-based regimens
alone or anthracycline-based regimens followed by taxane-
based regimens were the two most common protocols.
In all cases, radiation was delivered postoperatively
and after the completion of adjuvant chemotherapy.
The general indications for postmastectomy radiotherapy
included skin involvement, positive lymph node status,
and tumor size >5 cm. The radiation field included the
ipsilateral chest wall, the internal mammary chain, and
the supraclavicular fossa. Patients with positive hormone
receptor status received appropriate hormone therapy,
usually tamoxifen after surgery or completion of adjuvant
chemotherapy.
Follow-up and outcome
The follow-up period was calculated from the date of
SSM to the date of last patient contact. Local recurrence
was defined as a biopsy-proven recurrent tumor within
the ipsilateral anterior chest wall, including the skin,
subcutaneous tissue, and muscle. Regional recurrence
was defined as tumor involvement of ipsilateral axillary,
internal mammary, supraclavicular, or infraclavicular lymph
nodes. Recurrence at all other locations was classified
as distant metastases.
Patients were regularly followed-up every 3 to 6 months
for the first 5 years and every 12 months thereafter.
Reconstructed breasts were routinely checked by physical
examination and sonography. Annual mammography was
performed on the contralateral healthy breast. Abnormal
clinical findings might be evaluated by further studies,
including chest radiographs, sonography for liver, bone
scan, and tumor markers (CA-153 and carcinoembryonic
antigen).
Statistical analyses
Disease-free survival and overall survival were estimated
using the Kaplan–Meier method, and differences were
compared using the log-rank test. Factors that possibly
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grade, tumor size, lymph node status, American Joint
Committee on Cancer stage, and hormone receptor status,
were analyzed by univariate comparison. Subsequent
multivariate analysis was not performed because of the
small sample size. All analyses were performed using
Statistical Program for Social Sciences (SPSS 18.0 for




The characteristics of the 249 patients are presented in
Table 1. The median age at the time of diagnosis was 41
years (range, 22 to 62 years). All patients had invasiveTable 1 Patient characteristics
Variable Data






























Data presented as median (range) or n (%).breast cancer, and patients with stage II and stage III
disease accounted for two-thirds (67.1%) of the study
population (Table 2).
Treatment characteristics
Sixteen patients (6.4%) received neoadjuvant chemother-
apy with two to five cycles of 5-fluorouracil, anthracycline,
and cyclophosphamide (median, four cycles). One hun-
dred and ninety-six patients (78.7%) were treated with
adjuvant chemotherapy using anthracycline-based and/
or taxane-based regimens after surgery. The median
time from surgery to adjuvant chemotherapy was 31
days (range, 14 to 100 days). In only eight patients did
this time interval exceed 60 days. Additional adjuvant
radiotherapy was administered to 32 patients (12.9%)
after the completion of adjuvant chemotherapy. The
indication for radiation was lymph node metastasis and/or
large tumor size. One-half of the patients (50.6%) received
hormone therapy. Tamoxifen was administered to all these
patients, except for seven premenopausal patients who
received gonadotropin-releasing hormone analogues.
Recurrence
The median follow-up period was 53 months (range, 24
to 181 months). During the follow-up period, 55 patients
(22.1%) experienced recurrence. The patterns of first re-
currence are summarized in Table 3. The median time
to recurrence was 26 months (range, 2 to 70 months)
for all recurrences, 23 months (range, 2 to 64 months)
for locoregional recurrences, and 26 months (range, 8 to
70 months) for distant recurrences. Among the 16 patients
with locoregional recurrence, the first recurrence event
was isolated local recurrence in three patients and regional
recurrence alone in the other 13 patients.
Of the three patients with isolated local recurrence, all
recurrent lesions were detectable by palpation, despite
the small tumor size (0.8 to 2.2 cm in diameter). Diagnosis
was established by either needle cytology or excision bi-
opsy. Wide excision was subsequently performed followed
by radiotherapy and chemotherapy. Primary skin closure
could be accomplished in all cases without the use of
an additional flap or graft. TRAM flap removal was not
required during the resection of these recurrent lesions.
No further recurrence was detected in two patients.Table 2 Tumor staging







Table 3 Pattern of first breast cancer recurrence stratified
by stage
Recurrence
Stage n Local Regional Distant LR + D Overall n (%)
I 82 0 4 4 2 10 (12.2)
II 130 1 9 17 1 28 (21.5)
III 37 2 0 13 2 17 (45.9)
Total, n (%) 249 3 (1.2) 13 (5.2) 34 (13.7) 5 (2.0) 55 (22.1)
n, patient number; LR + D, concurrent locoregional and distant relapse.
Liang et al. World Journal of Surgical Oncology 2013, 11:194 Page 4 of 7
http://www.wjso.com/content/11/1/194However, the other patient experienced multiple liver
and bone metastases 26 months after the first relapse.
The 13 patients with regional lymph node recurrence
alone underwent lymph node dissection followed by
additional chemotherapy and/or radiotherapy. No further
recurrence occurred in 10 patients. In contrast, three
patients subsequently developed another recurrence 8,
10, and 56 months after the first relapse. In total, all but
one patient (15/16, 93.8%) with locoregional recurrence
as the first recurrence event were alive at the end of
the follow-up period.
Concurrent locoregional and distant recurrence occurred
in five patients (2.0%): three patients showed regional and
distant recurrence and two patients showed local, regional,
and distant recurrences. Local recurrences that occurred
in this group of patients presented as palpable nodulesFigure 1 Kaplan–Meier curves for locoregional relapse.or erythematous skin. Despite multidisciplinary treatments,
all five patients died, with a median survival of 13 months
after recurrence (range, 5 to −46 months). On stratification
according to tumor stage, distant recurrence was significantly
more frequent in patients with advanced-stage disease
(P <0.001), whereas no such correlation was observed
for locoregional recurrence (P = 0.722) (Figures 1 and 2).
In univariate analysis, factors associated with locoregional
recurrence after SSM and IBR were tumor size > 5 cm
(P = 0.042) and negative progesterone receptor status
(P = 0.004).
Twenty-six patients (10.4%) died during the follow-up
period, and all deaths were due to progression of meta-
static disease. Distant recurrence was the first recurrent
event in all of these patients except for one, in whom
ipsilateral supraclavicular lymph node involvement alone
was the first recurrence event. The average time to death
after first recurrence was 25 months (range, 1 to 75 months),
and 16 patients (61.5%) died within 2 years. The 5-year
overall, locoregional relapse-free, and distant relapse-free
survival rates were 89.7%, 90.8%, and 81.6%, respectively.
Discussion
This study included 249 consecutive patients with invasive
breast cancer who underwent SSM and IBR using pedicled
TRAM flap. The avoidance of patient selection and the
use of only one type of reconstruction method and a
Figure 2 Kaplan–Meier curves for distant relapse.
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thorough perspective on this treatment approach.
One concern regarding immediate reconstruction is
whether it hinders or delays the detection of local recur-
rence [14]. All five local recurrences (three local alone
and two concurrent local and systemic) that developed
in our series were detectable by physical examination
even in cases of recurrent tumor size <1 cm in diameter.
This result is consistent with two other series in which
all three and five of six local recurrences, respectively,
were detectable by physical examination [9,15]. Of 16
local recurrences after immediate TRAM flap reconstruc-
tion reported by Howard and colleagues [10], all were
identified by physical examination or subjective symptoms
that were subsequently confirmed by physical examination
or imaging studies. Our experience also highlights the
importance of physical examination, because the presence
of local recurrence may herald systemic metastasis either
synchronously or metachronously. Three patients with
local recurrences (3/5, 60.0%) developed distant metastasis
in our series.
In addition to physical examination, we routinely use
sonography for screening the reconstructed breast. The
ideal modalities for recurrence surveillance in this popu-
lation have not yet been determined. Some authors
recommended routine mammography and have used it
as an aid in the differentiation between fat necrosis andcancer. However, these two different lesions cannot always
be distinguished solely on the basis of mammographic
findings [9,16]. Pathological diagnosis remains the gold
standard, and biopsy is warranted for any new or persistent
lesion in the reconstructed breast.
The reported local recurrence rates after SSM and IBR
in studies with more than 100 patients range from 0.2
to 7.0% [17,18]. When limiting the study population to
patients with locally advanced breast cancer undergoing
the same procedure, the reported rates of local recurrence
are between 1 and 10% [6,11,19]. The local recurrence
rate for stage III patients (2/37, 5.5%) in our study is
comparable with that reported previously [6,11,19].
Despite the relatively small number of patients with stage
III disease in this series, our findings might strengthen
the rational use of SSM and immediate TRAM flap re-
construction in patients with advanced-stage disease. A
larger study with more patients is warranted to further
address this issue. Several studies have reported no signifi-
cant difference in recurrence pattern or incidence between
patients undergoing SSM and conventional mastectomy
[17,20]. Comparable results have also been observed for
patients with stage III disease [17].
The median time to locoregional recurrence was 23
months, 3 months shorter than that to distant relapse, in
our study. This finding is comparable with previously
reported results [10,21]. In a series of 1,392 breast
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colleagues found that locoregional recurrence occurred
within the first 3 years in most cases, with a peak in the
second year [22]. The recurrence rate then dropped
sharply and remained relatively constant over a long
period of time. However, recurrence occurring 10 years
after mastectomy has been reported, and a longer
follow-up time is warranted [21].
The rate of distant recurrence was significantly higher
in patients with advanced-stage disease, and distant
metastasis was the cause of all deaths that occurred in our
series. Despite multimodal treatment, > 60% of patients
died within 2 years after first distant relapse. In contrast
to the distant metastasis rate, the locoregional recurrence
rate did not increase significantly from stage I disease
to stage III disease. This difference may be ascribed to
the aggressive use of systemic therapy in this study.
In recent years, a trend of decreased local recurrence
rate has been observed [17]. Some authors considered this
decline attributable, at least in part, to the increasing use
of adjuvant therapy [17]. Our result may further support
the effectiveness of systemic treatment in reducing the
risk of locoregional recurrence and narrowing the gap
in outcome between different stages. Nevertheless, such
intensive adjuvant therapy can pose a heavy financial
burden to patients. In Taiwan, most of the cancer treatment
cost is covered by national health insurance. Thus, this type
of treatment was affordable for the majority of patients
in this series.
Based on our results, solitary local or regional recurrence
as the first recurrence event was associated with a better
prognosis than the development of locoregional recurrence
as part of systemic metastasis. Differentiation between
different recurrence patterns may thus be of great help
in predicting prognosis, and a thorough metastatic survey
at the time of the first recurrence is warranted. Recently,
the use of nipple-sparing mastectomy has been on the rise,
although its clinical application is usually limited to
prophylactic risk reduction and ductal carcinoma in
situ [23]. The oncologic safety of this procedure remains
the major concern that hampers its application. Our results
may further support the possible implementation of nip-
ple-sparing mastectomy for cases of advanced disease.Conclusion
Our study showed that SSM followed by IBR using
TRAM flap was an oncologically safe procedure. The
locoregional recurrence rate was acceptable even in
cases of advanced-stage disease. The TRAM flap did not
hinder the detection of recurrence. The first course of
postoperative chemotherapy could be delivered without
delay. In conjunction with adjuvant treatment, this pro-
cedure can be applicable to advanced-stage disease.Abbreviations
IBR: Immediate breast reconstruction; SSM: Skin-sparing mastectomy;
TRAM: Transverse rectus abdominis musculocutaneous.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TJ-L, B-WW, and H-TC participated in the design of the study and drafted the
manuscript. M-HY, Y-CC, and J-SC participated in data acquisition an analysis.
S-IL and K-TM carried out the literature review and revised the manuscript.
All authors read and approved the final manuscript.
Author details
1Division of General Surgery, Department of Surgery, Kaohsiung Veterans
General Hospital, 386 Ta-Chung 1st Road, Kaohsiung 813, Taiwan. 2National
Yang-Ming University School of Medicine, NO. 155, Sec. 2, Linong Street,
Taipei, Taiwan. 3Division of Plastic Surgery, Department of Surgery, Kaohsiung
Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung 813, Taiwan.
Received: 11 January 2013 Accepted: 5 August 2013
Published: 14 August 2013
References
1. Omranipour R, Bobin JY, Esouyeh M: Skin sparing mastectomy and
immediate breast reconstruction (SSMIR) for early breast cancer: eight
years single institution experience. World J Surg Oncol 2008, 6:43.
2. Spiegel AJ, Butler CE: Recurrence following treatment of ductal carcinoma
in situ with skin-sparing mastectomy and immediate breast
reconstruction. Plast Reconstr Surg 2003, 111:706–711.
3. Kinoshita S, Nojima K, Takeishi M, Imawari Y, Kyoda S, Hirano A, Akiba T,
Kobayashi S, Takeyama H, Uchida K, Morikawa T: Retrospective comparison
of non-skin-sparing mastectomy and skin-sparing mastectomy with
immediate breast reconstruction. Int J Surg Oncol 2011, 2011:876520.
4. Prabhu R, Godette K, Carlson G, Losken A, Gabram S, Fasola C, O'Regan R,
Zelnak A, Torres M: The impact of skin-sparing mastectomy with
immediate reconstruction in patients with stage III breast cancer treated
with neoadjuvant chemotherapy and postmastectomy radiation.
Int J Radiat Oncol Biol Phys 2012, 82:e587–e593.
5. Foster RD, Esserman LJ, Anthony JP, Hwang ES, Do H: Skin-sparing
mastectomy and immediate breast reconstruction: a prospective cohort
study for the treatment of advanced stages of breast carcinoma.
Ann Surg Oncol 2002, 9:462–466.
6. Ho AL, Tyldesley S, Macadam SA, Lennox PA: Skin-sparing mastectomy and
immediate autologous breast reconstruction in locally advanced breast
cancer patients: a UBC perspective. Ann Surg Oncol 2012, 19:892–900.
7. Lim W, Ko BS, Kim HJ, Lee JW, Eom JS, Son BH, Lee TJ, Ahn SH: Oncological
safety of skin sparing mastectomy followed by immediate
reconstruction for locally advanced breast cancer. J Surg Oncol 2010,
102:39–42.
8. Medina-Franco H, Vasconez LO, Fix RJ, Heslin MJ, Beenken SW, Bland KI,
Urist MM: Factors associated with local recurrence after skin-sparing
mastectomy and immediate breast reconstruction for invasive breast
cancer. Ann Surg 2002, 235:814–819.
9. Shaikh N, LaTrenta G, Swistel A, Osborne FM: Detection of recurrent breast
cancer after TRAM flap reconstruction. Ann Plast Surg 2001, 47:602–607.
10. Howard MA, Polo K, Pusic AL, Cordeiro PG, Hidalgo DA, Mehrara B, Disa JJ:
Breast cancer local recurrence after mastectomy and TRAM flap
reconstruction: incidence and treatment options. Plast Reconstr Surg 2006,
117:1381–1386.
11. Downes KJ, Glatt BS, Kanchwala SK, Mick R, Fraker DL, Fox KR, Solin LJ,
Bucky LP, Czerniecki BJ: Skin-sparing mastectomy and immediate
reconstruction is an acceptable treatment option for patients with
high-risk breast carcinoma. Cancer 2005, 103:906–913.
12. Styblo TM, Lewis MM, Carlson GW, Murray DR, Wood WC, Lawson D, Landry
J, Hughes L, Nahai F, Bostwick J 3rd: Immediate breast reconstruction for
stage III breast cancer using transverse rectus abdominis
musculocutaneous (TRAM) flap. Ann Surg Oncol 1996, 3:375–380.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer
Staging Manual. 7th edition. New York: Springer; 2010.
Liang et al. World Journal of Surgical Oncology 2013, 11:194 Page 7 of 7
http://www.wjso.com/content/11/1/19414. Patel RT, Webster DJ, Mansel RE, Hughes LE: Is immediate postmastectomy
reconstruction safe in the long-term? Eur J Surg Oncol 1993, 19:372–375.
15. Helvie MA, Wilson TE, Roubidoux MA, Wilkins EG, Chang AE: Mammographic
appearance of recurrent breast carcinoma in six patients with TRAM flap
breast reconstructions. Radiology 1998, 209:711–715.
16. Mund DF, Wolfson P, Gorczyca DP, Fu YS, Love SM, Bassett LW:
Mammographically detected recurrent nonpalpable carcinoma
developing in a transverse rectus abdominus myocutaneous flap. A case
report. Cancer 1994, 74:2804–2807.
17. Yi M, Kronowitz SJ, Meric-Bernstam F, Feig BW, Symmans WF, Lucci A,
Ross MI, Babiera GV, Kuerer HM, Hunt KK: Local, regional, and systemic
recurrence rates in patients undergoing skin-sparing mastectomy
compared with conventional mastectomy. Cancer 2011, 117:916–924.
18. Kroll SS, Khoo A, Singletary SE, Ames FC, Wang BG, Reece GP, Miller MJ,
Evans GR, Robb GL: Local recurrence risk after skin-sparing and
conventional mastectomy: a 6-year follow-up. Plast Reconstr Surg 1999,
104:421–425.
19. Foster RD, Hansen SL, Esserman LJ, Hwang ES, Ewing C, Lane K, Anthony JP:
Safety of immediate transverse rectus abdominis myocutaneous breast
reconstruction for patients with locally advanced disease. Arch Surg 2005,
140:196–198. discussion 199–200.
20. Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti R, Hadjiminas DJ:
Comparison of skin-sparing mastectomy versus non-skin-sparing
mastectomy for breast cancer: a meta-analysis of observational studies.
Ann Surg 2010, 251:632–639.
21. Romics L Jr, Chew BK, Weiler-Mithoff E, Doughty JC, Brown IM, Stallard S,
Wilson CR, Mallon EA, George WD: Ten-year follow-up of skin-sparing
mastectomy followed by immediate breast reconstruction. Br J Surg 2012,
99:799–806.
22. Crowe JP Jr, Gordon NH, Antunez AR, Shenk RR, Hubay CA, Shuck JM:
Local–regional breast cancer recurrence following mastectomy.
Arch Surg 1991, 126:429–432.
23. de Alcantara FP, Capko D, Barry JM, Morrow M, Pusic A, Sacchini VS:
Nipple-sparing mastectomy for breast cancer and risk-reducing surgery:
the Memorial Sloan-Kettering Cancer Center experience. Ann Surg Oncol
2011, 18:3117–3122.
doi:10.1186/1477-7819-11-194
Cite this article as: Liang et al.: Recurrence after skin-sparing mastectomy
and immediate transverse rectus abdominis musculocutaneous flap
reconstruction for invasive breast cancer. World Journal of Surgical Oncology
2013 11:194.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
